V2726
antibody from NSJ Bioreagents
Targeting: MUC1
ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM
Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Immunohistochemistry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V2726 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- MUC1 Antibody
- Antibody type
- Monoclonal
- Antigen
- Human milk-fat globule membranes (HMFGM) was used as the immunogen for the MUC1 antibody.
- Description
- Protein G purified antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- 139H2
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the MUC1 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Loss of E-cadherin independently predicts the lymph node status in colorectal cancer.
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.
Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Evaluation of ocular surface disorders: a new diagnostic tool based on impression cytology and confocal laser scanning microscopy.
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
MUC1 is a promising therapeutic target for prostate cancer therapy.
Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.
Karamitopoulou E, Zlobec I, Patsouris E, Peros G, Lugli A
Pathology 2011 Feb;43(2):133-7
Pathology 2011 Feb;43(2):133-7
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM, Lugli A
Human pathology 2011 Dec;42(12):1888-96
Human pathology 2011 Dec;42(12):1888-96
Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.
Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A
International journal of oncology 2010 Sep;37(3):707-18
International journal of oncology 2010 Sep;37(3):707-18
Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Karamitopoulou E, Zlobec I, Koumarianou A, Patsouris ES, Peros G, Lugli A
Cancer 2010 Oct 1;116(19):4474-86
Cancer 2010 Oct 1;116(19):4474-86
Evaluation of ocular surface disorders: a new diagnostic tool based on impression cytology and confocal laser scanning microscopy.
Barbaro V, Ferrari S, Fasolo A, Pedrotti E, Marchini G, Sbabo A, Nettis N, Ponzin D, Di Iorio E
The British journal of ophthalmology 2010 Jul;94(7):926-32
The British journal of ophthalmology 2010 Jul;94(7):926-32
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
Karamitopoulou E, Lugli A, Panayiotides I, Karakitsos P, Peros G, Rallis G, Patsouris ES, Terracciano L, Zlobec I
Histopathology 2010 Aug;57(2):233-43
Histopathology 2010 Aug;57(2):233-43
MUC1 is a promising therapeutic target for prostate cancer therapy.
Li Y, Cozzi PJ
Current cancer drug targets 2007 May;7(3):259-71
Current cancer drug targets 2007 May;7(3):259-71
Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.
Lugli A, Zlobec I, Baker K, Minoo P, Tornillo L, Terracciano L, Jass JR
Journal of clinical pathology 2007 May;60(5):534-9
Journal of clinical pathology 2007 May;60(5):534-9
No comments: Submit comment
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of formalin-fixed, paraffin-embedded human lung cancer stained with MUC1 antibody (139H2).
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of formalin-fixed, paraffin-embedded human breast cancer stained with MUC1 antibody (139H2).
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of formalin-fixed, paraffin-embedded human endometrial carcinoma stained with MUC1 antibody (139H2).